Jamnagerwalla Murtaza, Tay Rebecca, Steel Malcolm, Keck Jamie, Jones Ian, Faragher Ian, Gibbs Peter, Wong Rachel
1 Department of Surgery, Eastern Health, Melbourne, Australia 2 Department of Medical Oncology, Eastern Health, Melbourne, Australia 3 Department of Surgery, Royal Melbourne Hospital, Melbourne, Australia 4 Department of Surgery, Western Health, Melbourne, Australia 5 Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia 6 Department of Medical Oncology, Western Health, Melbourne, Australia 7 Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia 8 University of Melbourne, Melbourne, Australia 9 Monash University, Faculty of Medicine, Nursing and Health Sciences, Melbourne, Australia.
Dis Colon Rectum. 2016 Oct;59(10):916-24. doi: 10.1097/DCR.0000000000000659.
Surgical complications after resection for locally advanced rectal cancer may influence adjuvant treatment outcomes and survival. Few studies have examined this effect.
This study aimed to examine the impact of surgical complications on adjuvant therapy delivery and survival in patients with locally advanced rectal cancer treated with long-course chemoradiation followed by surgery.
This is a retrospective analysis of a prospectively collected multicenter colorectal cancer database.
Data were collected from the Australian Comprehensive Cancer Outcomes and Research Database.
All patients who completed neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer between January 2003 and December 2014 were selected.
We examined the types and frequency of surgical complications and their impact on the delivery of adjuvant chemotherapy and survival.
Data were available for 517 patients, of whom 147 (28%) had a surgical complication. Patients with a surgical complication were less likely to commence adjuvant chemotherapy (33% vs 66%; p = 0.0005) and more likely to have adjuvant treatment commencing more than 8 weeks from surgery (71.8% vs 21.2%; p = 0.004). Wound-related complications (p = 0.001), return to operating theater (p = 0.004), and readmission within 30 days (p = 0.02) had the most significant negative impact on the delivery of adjuvant chemotherapy. Surgical complications were significantly more likely in males (31.6% vs 20.8%, p = 0.003) and laparoscopic converted cases (47.8% vs 21.8%, p = 0.03). For the entire patient population, adjuvant chemotherapy compared with surveillance was not associated with an improved recurrence-free survival (HR, 1.06; p = 0.83) but was associated with an improved overall survival (HR, 0.53; p = 0.04).
This study was limited by its retrospective design.
Surgical complications in patients having surgery following neoadjuvant chemoradiotherapy for locally advanced rectal cancer were associated with significantly reduced uptake and delays to receiving adjuvant therapy. Surgical complications, however, were not associated with either significantly reduced recurrence-free or overall survival. Adjuvant chemotherapy delivery was associated with improved overall survival.
局部晚期直肠癌切除术后的手术并发症可能会影响辅助治疗效果和生存率。很少有研究探讨这种影响。
本研究旨在探讨手术并发症对接受长程放化疗后手术的局部晚期直肠癌患者辅助治疗的实施及生存的影响。
这是一项对前瞻性收集的多中心结直肠癌数据库的回顾性分析。
数据来自澳大利亚综合癌症结局与研究数据库。
选取2003年1月至2014年12月间完成新辅助放化疗后行局部晚期直肠癌手术的所有患者。
我们研究了手术并发症的类型和发生率及其对辅助化疗实施和生存的影响。
517例患者有可用数据,其中147例(28%)发生手术并发症。发生手术并发症的患者开始辅助化疗的可能性较小(33%对66%;p = 0.0005),且更有可能在术后8周以上开始辅助治疗(71.8%对21.2%;p = 0.004)。与伤口相关的并发症(p = 0.001)、返回手术室(p = 0.004)和30天内再次入院(p = 0.02)对辅助化疗的实施产生了最显著的负面影响。男性(31.6%对20.8%,p = 0.003)和腹腔镜中转手术病例(47.8%对21.8%,p = 0.03)发生手术并发症的可能性显著更高。对于整个患者群体,辅助化疗与观察相比,无复发生存率未得到改善(HR,1.06;p = 0.83),但总生存率得到改善(HR,0.53;p = 0.04)。
本研究受其回顾性设计的限制。
局部晚期直肠癌新辅助放化疗后手术患者的手术并发症与辅助治疗的接受率显著降低和延迟接受有关。然而,手术并发症与无复发生存率或总生存率的显著降低均无关。辅助化疗的实施与总生存率的改善有关。